With a number of difference payment programs being tested, it’s important to have a sophisticated evaluation of these programs to really understand their impact on quality and cost, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
With a number of difference payment programs being tested, it’s important to have a sophisticated evaluation of these programs to really understand their impact on quality and cost, said Allison Brennan, MPP, senior vice president of government affairs for the National Association of ACOs.
Transcript
How have accountable care organizations (ACOs) compared with other payment models when it comes to improving care and reducing costs?
So, there are definitely a number of payment models out there. One thing that we’ve emphasized with the ACO programs is the need to have a sophisticated evaluation of these programs. So, we need to look beyond just the performance of the ACO relative to their CMS benchmark. And we’ve actually recently put out data that does show significant savings for the MSSP program, similarly CMMI {Center for Medicare and Medicaid Innovation] has done sophisticated analyses on the first year of the Next Generation ACO model, which also showed significant savings.
As we look at other CMMI programs, it’s really important to use similar types of evaluations as we look across programs. That will allow us to have kind of similar results or comparisons that are on even playing fields. And a lot of these programs are still relatively new, so we need a few years of data before we can really draw conclusions.
But we have seen strong performance in data from ACOs in terms of cost reductions and quality. In some other programs we’ve seen kind of one or the other or sometimes we see improvements in quality and cost kind of neutral, but maybe when we factor in the additional payments to those programs then it’s not a net savings to Medicare. So, I think that overall in comparison to other programs, ACOs are showing increasingly positive results.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
The White House has called out the Republican Study Committee’s budget proposal for backing legislation that would put restrictions on abortion access; nearly 108,000 Americans died of drug overdoses in 2022; surgeons in Boston have transplanted a kidney from a genetically engineered pig into an ailing 62-year-old man.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More